Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal insulin plus oral semaglutide for cognitive improvement in older adults with metabolic syndrome and mild cognitive impairment
MOH_2022-07-04_011888Phase 2Not yet recruiting
- Sponsor
- פרופ' מיכל שניידר בארי
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide and human insulin in Mild Cognitive Impairment (MCI) (4 arms), sponsored by פרופ' מיכל שניידר בארי. Primary endpoint: Not specified. Planned start May 2022; status: not yet recruiting.
02
Drugs
semaglutidehuman insulin
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on MOH_2022-07-04_011888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-04_011888.